Corcept is leading the way in the research and development of cortisol modulators, molecules that regulate cortisol activity at the glucocorticoid receptor (GR). To date, we have discovered more than 1,000 selective proprietary cortisol modulators.
In 2012, we received FDA approval of Korlym® (mifepristone), the first approved treatment for hypercortisolism (Cushing’s syndrome).
Today, our team and collaborators continue to unlock the possibilities of cortisol modulation as a way to treat serious diseases. With more than 30 ongoing studies across a wide range of disease areas, including endocrinology, oncology, metabolism, and neurology, we remain dedicated to advancing the possibilities of cortisol modulation.
What began as a ripple of scientific truth is now poised to unleash a sea change of discovery representing a fundamental shift in the way we understand and treat disease.
The Senior Manager of Pharmacokinetics will support the Clinical Pharmacology and Pharmacokinetics Team to provide analysis and interpretation of all pharmacokinetic and pharmacodynamic data and for the design of human and non-clinical studies.
Responsibilities:
- Serving as the pharmacokinetic point person on both animal and human studies
- Conducting analyses of nonclinical and clinical data including, but not limited to, pharmacokinetic analyses and pharmacokinetic/pharmacodynamic analyses
- Plotting and evaluating animal and human pharmacokinetic data
- Performing in vitro in vivo correlations to link in vitro drug data to in vivo performance
- Writing pharmacokinetic and/or toxicokinetic reports
- Reviewing bioanalytical and method validation reports
- Contributing to clinical pharmacology development plans and regulatory submissions, including INDs, IBs and NDAs etc.
- Strictly adhering to agreed timelines to insure prompt and accurate execution of deliverables
- Providing subject matter expertise in cross functional teams and collaborating with other team members
- Contributing to study protocols, analysis plans, bioanalytical reports, and study reports
- This headquarters-based role requires on-site attendance three days a week
Preferred Skills, Qualifications and Technical Proficiencies:
- Hands-on and in-depth knowledge of current versions of pharmacokinetic and data analysis software programs such as Excel, Phoenix WinNonlin and GraphPad etc.
- Hands-on and in-depth knowledge of current versions PowerPoint and Word etc.
- Thorough understanding of current regulatory requirements
- Able to perform detailed work accurately and in a timely manner
- Excellent written and oral communication skills
- Proven ability to critically analyze problems and provide creative solutions
- Discipline and confidence to work in teams and to work independently
Preferred Education and Experience:
- 2-5 years of industry experience and a PhD, PharmD or MD degree with emphasis in pharmacokinetics, clinical pharmacology, or a related field
The pay range that the Company reasonably expects to pay for this headquarters-based position is $181,000 - $212,900; the pay ultimately offered may vary based on legitimate considerations, including geographic location, job-related knowledge, skills, experience, and education.
Applicants must be currently authorized to work in the United States on a full-time basis.
For information on how Corcept collects, uses, discloses, protects, and otherwise processes personal information and an explanation of the rights and choices available to you with respect to your personal information, please refer to our Privacy Notice link.
Corcept appreciates the commitment and hard work of all our team members as we strive to discover and develop novel treatments for patients with serious unmet medical needs.
Please visit our website at: https://www.corcept.com/
Corcept is an Equal Opportunity Employer
Corcept will not conduct interviews via text message or messaging platforms and will not ask you to download anything as part of your interview. Though we use third-party tools to help with advertising our jobs, please be vigilant in checking that the communication is in fact coming from Corcept.